All In Biotech

Drug Trial Radar · NCT05042362

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

Aug 27, 2021

Primary completion

Jul 25, 2023

Study completion Nov 27, 2023

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Sep 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo looks like a treatment but does not have any medicine in it. To compare these study treatments, the doctors will ask the participants to record information about the participants' hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe the hot flashes are. The researchers will look at the results from before treatment, after 4 weeks, and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants who take elinzanetant will take it for 26 weeks. The participants who take the placebo will take it for 12 weeks and then take elinzanetant for the next 14 weeks. During the study, the participants will visit the site approximately 9 times and perform 1 visit by phone. Each participant will be in the study for approximately 36 weeks. The treatment duration will be 26 weeks. During the study, the participants will: * record information about the participants' hot flashes in an electronic diary * answer questions about the participants' symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines the participants are taking and if the participants are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if doctors do not think the adverse events might be related to the study treatments.

Conditions

  • Vasomotor Symptoms Associated With Menopause
  • Hot Flashes

Interventions

  • Elinzanetant (BAY3427080)Drug

    120 mg elinzanetant orally once daily

  • PlaceboDrug

    Matching placebo orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 4 (Assessed by Hot Flash Daily Diary [HFDD]).Time frame: From baseline to Week 4
  2. Mean Change in Frequency of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).Time frame: From baseline to Week 12
  3. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 4 (Assessed by HFDD).Time frame: From baseline to Week 4
  4. Mean Change in Severity of Moderate to Severe HF From Baseline to Week 12 (Assessed by HFDD).Time frame: From baseline to Week 12

Locations

99 sites in 8 countries. Site status is shown where the registry gives one.

  • Alabama Clinical Therapeutics | Birmingham, AL

    Birmingham, Alabama

  • Central Research Associates | Birmingham, AL

    Birmingham, Alabama

  • Mesa Obstetricians and Gynecologists | Research Department

    Mesa, Arizona

  • MomDoc Women's Health Research | Scottsdale, AZ

    Scottsdale, Arizona

  • Noble Clinical Research | Tucson, AZ

    Tucson, Arizona

  • Del Sol Research | Women Health studies

    Tucson, Arizona

  • Applied Research Center of Arkansas

    Little Rock, Arkansas

  • Alliance Research Institute | Bell Gardens, CA

    Bell Gardens, California

  • Diagnamics | Encinitas, CA

    Encinitas, California

  • Om Research LLC | Lancaster, CA

    Lancaster, California

  • Northern California Research | Sacramento

    Sacramento, California

  • IntimMedicine | Washington, DC

    Washington D.C., District of Columbia

  • AMR - Fort Myers, FL

    Fort Myers, Florida

  • Suncoast Clinical Research Inc | Pinellas

    Palm Harbor, Florida

  • Physician Care Clinical Research LLC | Sarasota, FL

    Sarasota, Florida

  • Medisense Inc. | Atlanta, GA

    Atlanta, Georgia

  • Paramount Research Solutions | College Park Location

    College Park, Georgia

  • Soapstone Center for Clinical Research, Inc. | Decatur, GA

    Decatur, Georgia

  • Drug Studies America

    Marietta, Georgia

  • M3 Wake Research Atlanta

    Sandy Springs, Georgia

  • Clinical Research Prime

    Idaho Falls, Idaho

  • Investigators Research Group, LLC

    Brownsburg, Indiana

  • The Iowa Clinic - Ankeny

    Ankeny, Iowa

  • Southern Clinical Research Associates | Metairie, LA

    Metairie, Louisiana

  • Continental Clinical Solutions | Towson, MD

    Towson, Maryland

  • Revive Research Institute, Inc. - Women's Health

    Dearborn Heights, Michigan

  • Valley OBGYN

    Saginaw, Michigan

  • Women's Clinic of Lincoln, P.C. | Lincoln, NE

    Lincoln, Nebraska

  • Jubilee Clinical Research Inc | Las Vegas, NV

    Las Vegas, Nevada

  • Affiliated Clinical Research, Inc. | Las Vegas, NV

    Las Vegas, Nevada

  • M3 Wake Research - Clinical Research Center of Nevada

    Las Vegas, Nevada

  • The Center for Womens Health & Wellness, LLC | Lawrenceville, NJ

    Lawrenceville, New Jersey

  • Rutgers Robert Wood Johnson Medical School

    New Brunswick, New Jersey

  • Velocity Clinical Research - Albuquerque

    Albuquerque, New Mexico

  • Bosque Women's Care | Albuquerque, NM

    Albuquerque, New Mexico

  • Circuit Clinical | OB GYN Associates of WNY

    West Seneca, New York

  • OnSite Clinical Solutions - Charlotte

    Charlotte, North Carolina

  • M3 Wake Research | Raleigh, NC

    Raleigh, North Carolina

  • Unified Women's Clinical Research | Lyndhurst Clinical Research, Winston-Salem, NC

    Winston-Salem, North Carolina

  • Axia Women's Health - Anderson Township

    Cincinnati, Ohio

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.